Michael May, Pancreas Cancer Clinical Investigator at Memorial Sloan Kettering Cancer Center, shared a post on X:
“Already giving patients daraxonrasib off trial only 21 days after the practice-changing results were presented at ASCO 2026. Thank you to Memorial Sloan Kettering Cancer Center and Revolution Medicines for allowing us to fill this unmet need safely and efficiently.”
Other articles featuring Dr. May on OncoDaily.